ASX 200 morning report – ANZ, NEA & QBE shares in focus
Drew Meredith, CFP
May 6, 2021
The S&P/ASX 200 (INDEXASX:XJO) reached a 14-month high on Wednesday.
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX:XJO) reached a 14-month high on Wednesday.
The Mayne Pharma Group Ltd (ASX: MYX) share price soared
BetaShares Australia 200 ETF (ASX: A200) might be one of
The Altium Limited (ASX: ALU) share price has risen by
In this article you’ll find two tips to invest better
The S&P/ASX 200 (ASX: XJO) fell 0.3% to begin the
The CSL Limited (ASX:CSL) share price could be a long-term
The S&P/ASX 200 (ASX: XJO) finished the week flat on
Will the Flight Centre Travel Group Ltd (ASX: FLT) share
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.